ID   URUM_HYDBH              Reviewed;          27 AA.
AC   P0DTB9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   25-MAY-2022, entry version 4.
DE   RecName: Full=Urumin {ECO:0000303|PubMed:28423338};
DE   AltName: Full=Host defense peptide {ECO:0000303|PubMed:28423338};
DE            Short=HDP {ECO:0000303|PubMed:28423338};
OS   Hydrophylax bahuvistara (Wide-spread fungoid frog).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia;
OC   Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Hydrophylax.
OX   NCBI_TaxID=1690667;
RN   [1]
RP   PROTEIN SEQUENCE, FUNCTION, SYNTHESIS, MUTAGENESIS OF PRO-2; PHE-7; ARG-11;
RP   TRP-12; ASP-13; GLN-15; CYS-16; HIS-17; PHE-19; SER-20; ASN-21; ILE-24 AND
RP   CYS-26, AND PHARMACEUTICAL.
RC   TISSUE=Skin secretion;
RX   PubMed=28423338; DOI=10.1016/j.immuni.2017.03.018;
RA   Holthausen D.J., Lee S.H., Kumar V.T., Bouvier N.M., Krammer F.,
RA   Ellebedy A.H., Wrammert J., Lowen A.C., George S., Pillai M.R., Jacob J.;
RT   "An amphibian host defense peptide is virucidal for human H1 hemagglutinin-
RT   bearing influenza viruses.";
RL   Immunity 46:587-595(2017).
CC   -!- FUNCTION: Amphibian peptide that shows viricidal activity against human
CC       H1N1 influenza A virus. It specifically targets the conserved stalk
CC       region of H1 hemagglutinin, and acts by actively destroying influenza
CC       virions. It shows a reduced activity on human H3N2 influenza A virus
CC       and no activity against other viruses (HIV, SIV, HSV-II, hepatitis C,
CC       Ebola, Zika, and Dengue viruses). In vivo, the peptide also protects
CC       mice infected with mouse-adapted influenza virus from lethal influenza
CC       infection. The peptide synthesized in D-amino acids is inactive.
CC       {ECO:0000269|PubMed:28423338}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:28423338}.
CC   -!- TISSUE SPECIFICITY: Expressed by the skin glands.
CC       {ECO:0000305|PubMed:28423338}.
CC   -!- PHARMACEUTICAL: Could contribute to first-line antiviral treatments
CC       during outbreaks of flu, particularly as host defense peptides are less
CC       prone to resistance than conventional drug therapies.
CC       {ECO:0000305|PubMed:28423338}.
CC   -!- MISCELLANEOUS: The name urumin is given by authors from the word
CC       'urumi', which is a deadly whip sword that originates from the same
CC       geographical region as H.bahuvistara. {ECO:0000305|PubMed:28423338}.
CC   -!- WEB RESOURCE: Name=The antimicrobial peptide database;
CC       URL="https://wangapd3.com/database/query_output.php?ID=02846";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   AlphaFoldDB; P0DTB9; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0006952; P:defense response; IEA:UniProtKB-KW.
DR   GO; GO:0050688; P:regulation of defense response to virus; IEA:UniProtKB-KW.
PE   1: Evidence at protein level;
KW   Amphibian defense peptide; Antiviral protein; Direct protein sequencing;
KW   Pharmaceutical; Secreted.
FT   PEPTIDE         1..27
FT                   /note="Urumin"
FT                   /id="PRO_0000449323"
FT   MUTAGEN         2
FT                   /note="P->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         7
FT                   /note="F->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         11
FT                   /note="R->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         12
FT                   /note="W->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         13
FT                   /note="D->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         15
FT                   /note="Q->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         16
FT                   /note="C->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         17
FT                   /note="H->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         19
FT                   /note="F->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         20
FT                   /note="S->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         21
FT                   /note="N->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         24
FT                   /note="I->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
FT   MUTAGEN         26
FT                   /note="C->A: Decrease in antiviral activity."
FT                   /evidence="ECO:0000269|PubMed:28423338"
SQ   SEQUENCE   27 AA;  2961 MW;  DD5AF8DB414BAB86 CRC64;
     IPLRGAFING RWDSQCHRFS NGAIACA